Key result
Higher pan-immune-inflammation value predicts no-reflow in STEMI patients undergoing PCI.
Key points are not available for this paper at this time.
May aid no-reflow risk stratification in STEMI PCI; leaves open prospective validation and therapeutic targeting.
< 0.001). According to our findings, an increase in PIV is an independent predictor of noreflow in patients with STEMI.
No takes yet. Share an insight, caveat, or question.
Bayramoğlu et al. (2023) studied this question. An increase in pan-immune-inflammation value is an independent predictor of no-reflow in patients with STEMI undergoing percutaneous coronary intervention (p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: